It is becoming increasingly evident that infertility treatment is no longer a matter of medicine alone; it is a question of health policy and social structure. This reality is starkly illustrated by comparing the accessibility of IVF between the United Kingdom and South Korea.
The UK Model: The Financial Ceiling In the UK, the National Health Service (NHS) provides IVF funding in principle, but access is severely restricted by regional budget allocations. In many districts, support is limited to a single cycle. Once that attempt fails, patients are forced to navigate the rest of their fertility journey at their own expense. With the cost of a single IVF cycle in the UK reaching approximately $20,000 to $30,000 (roughly 30 million KRW), the “sustainability” of treatment is dictated entirely by personal wealth. Failure often marks the end of the road, transforming a medical choice into a forced abandonment.
The South Korean Model: The Cumulative Opportunity In contrast, South Korea employs a structure designed for repeated attempts. Through the National Health Insurance system, patients can receive coverage for up to 20 cycles of IVF and 5 cycles of IUI (Intrauterine Insemination). The policy is fundamentally engineered on the premise that IVF is a process, not a one-time event.
This architecture is multi-layered:
- State Coverage: Health insurance subsidizes a significant portion of procedural costs.
- Additional Subsidies: Government-led fertility support programs and supplemental local government grants further reduce the out-of-pocket costs for the initial treatment phases.
- The “Reset” Mechanism: Crucially, if a patient succeeds in a live birth, the entitlement to 20 IVF cycles and 5 IUI cycles is reset for the next child, reinforcing the policy as a long-term strategy for family building.
The Gap Between Ending and Continuing While some aspects of treatment—such as genetic testing or specific premium medications—remain non-reimbursable and accumulate as a financial burden over multiple cycles, the structural difference remains clear:
- The UK System: Offers a single opportunity, where failure is a terminal point.
- The South Korean System: Guarantees a wide range of attempts, where failure is a bridge to the next cycle.
The Final Verdict: Who Can Afford to Try? Medical technology is advancing rapidly, but clinical outcomes are not determined solely by the skill of the embryologist or the precision of the hormone protocol. Success is fundamentally tied to “persistence.”
It is not just about whether you can start treatment, but whether you can afford to continue it until success is achieved. In this critical metric of “the sustainability of attempts,” South Korea stands out as a country that institutionally protects the patient’s right to continue trying. When fertility care is viewed through the lens of longevity and persistence, the gap between these two systems is not just significant—it is transformative.
Disclaimer: This content is provided for informational purposes, based on reporting on infertility and public policy data. Medical judgments and treatment decisions must always be made in consultation with professional medical personnel. Image: AI-generated (ChatGPT, OpenAI) / Visual reference for illustrative purposes only.